ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0518

Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis

RA – Treatment Poster I

10:30AM-12:30AM: Abstract Number: PP06

Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0087

SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

SLE – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0017

Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

10:30AM-12:30PM: Abstract Number: 0572

Synergistic Impact of the Non-radiographic Axial Spondyloarthritis Subtype and Female Sex on First-Line Biologic Discontinuation : A Study of Interaction Effects

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0044

Synovial Phosphoproteomic Profiling in Early and Advanced Rheumatoid Arthritis (R4RA Trial) Identifies Specific Signaling Pathways Linked to Distinct Pathotypes

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0608

Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0173

Systemic Lupus Erythematosus Mortality—United States, 2018–2022

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0251

T-SPOT.TB and TST in Diagnosing Active Tuberculosis in Patients with Rheumatic Immune Diseases: A Fully Paired Comparative Diagnostic Test Accuracy Study

Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0040

Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0091

Targeting Endothelial Dysfunction in Lupus Nephritis: Effect of Sepiapterin, a Drug That Restores Endothelial Nitric Oxide Synthase Function, in a Murine Model of Lupus Nephritis

SLE – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0275

Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0072

The Association Between Activation of Inflammasome and HLA-B27 in Dendritic Cells of Patients with Axial Spondyloarthritis

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0388

The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0133

The Association Between Gout and Gallstone Disease: US General Population Analysis

Epidemiology & Public Health Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.